Last reviewed · How we verify
taxol plus everolimus — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
taxol plus everolimus (taxol plus everolimus) — Samsung Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| taxol plus everolimus TARGET | taxol plus everolimus | Samsung Medical Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- taxol plus everolimus CI watch — RSS
- taxol plus everolimus CI watch — Atom
- taxol plus everolimus CI watch — JSON
- taxol plus everolimus alone — RSS
Cite this brief
Drug Landscape (2026). taxol plus everolimus — Competitive Intelligence Brief. https://druglandscape.com/ci/taxol-plus-everolimus. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab